Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- ASKA Rolls Out Contraceptive Pill Slinda in Japan
July 1, 2025
- 17 of 23 Japan Drug Makers Hike Average Pay in FY2024, 7 Firms Break 10-Million-Yen Mark
July 1, 2025
- J-TEC Targets 1,000 Knee OA Cases Per Year for JACC: CEO
June 30, 2025
- Rakuten, Taiwan’s Orient EuroPharma Ink Photoimmunotherapy Deal
June 30, 2025
- Asahi Kasei Kicks Off Japan PIII for Recomodulin for CIPN
June 30, 2025
- Moderna Japan Files Updated COVID Shot for Age 11 and Under
June 30, 2025
- LP.8.1-Adapted Novavax COVID Vaccine Filed in Japan: Takeda
June 30, 2025
- Fuji Pharma Filed for OTC Approval of Emergency Contraceptive Last October
June 27, 2025
- Chugai Files Alecensa for ALK-Positive Solid Tumors in Japan
June 27, 2025
- Kyowa Kirin Wins Japan Nod for Lumicef Pen Injector
June 27, 2025
- ASKA Launches Japan PIII of Relugolix Combo for Endometriosis
June 26, 2025
- Japan Approves Crysvita Prefilled Syringe: Kyowa Kirin
June 26, 2025
- SanBio Pushes Back Shipment Approval Timeline for Cell Therapy Akuugo
June 26, 2025
- Takeda Zeros in on US Successor Ahead of 2026 CEO Transition
June 26, 2025
- Japan Pharma Market to Reach 12.28 Trillion Yen by FY2029: IQVIA
June 25, 2025
- Novartis Taps Cancer Institute Hospital as Priority Trial Site in Japan
June 25, 2025
- FDA Approves Daiichi’s Datroway for EGFR Lung Cancer
June 25, 2025
- Medipal/JCR’s MPS IIIB Therapy Earns Orphan Status in Europe
June 25, 2025
- Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
June 24, 2025
- Axcelead, Superluminal Pair Up to Target Challenging Molecular Mechanisms
June 24, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…